"Taxoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
| Descriptor ID |
D043823
|
| MeSH Number(s) |
D02.455.426.392.368.242.888 D02.455.849.291.850
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Taxoids".
Below are MeSH descriptors whose meaning is more specific than "Taxoids".
This graph shows the total number of publications written about "Taxoids" by people in this website by year, and whether "Taxoids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 3 | 4 |
| 2017 | 10 | 11 | 21 |
| 2018 | 1 | 8 | 9 |
| 2019 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Taxoids" by people in Profiles.
-
Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. Cancer Treat Rev. 2019 Sep; 79:101885.
-
Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition. Cancer Sci. 2019 Jun; 110(6):2014-2021.
-
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs. 2019 Mar; 79(4):381-400.
-
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. J Neurooncol. 2019 May; 142(3):455-462.
-
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treat Rev. 2019 Mar; 74:35-42.
-
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019 Feb; 174(1):27-37.
-
Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective. Asia Pac J Clin Oncol. 2018 Nov; 14 Suppl 5:5-8.
-
CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018 07; 16(7):e2005869.
-
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. Cochrane Database Syst Rev. 2018 07 23; 7:CD012838.
-
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018 09; 78(13):1035-1041.